NCT06563804 2026-03-30
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Servier
Phase 1/2 Terminated
Servier
Prelude Therapeutics
University Health Network, Toronto
AbbVie
AstraZeneca
Swiss Cancer Institute
AbbVie